B Cell Modulation Strategies in Autoimmune Diseases: New Concepts

Area of Science:

• Immunology
• Autoimmunity
• Cell Biology

Background:

• B cells are key players in autoimmune diseases, mediating pathology through antibody production, T cell help, and cytokine release.
• Advances in understanding B cell biology have led to targeted therapies like anti-CD20 antibodies and Bruton's tyrosine kinase inhibitors.

Purpose of the Study:

• To discuss current concepts and future directions for B cell modulating therapies in autoimmune diseases.
• To highlight the role of regulatory B cells and their implications for B cell depleting therapies.
• To focus specifically on the application of these therapies in pemphigus.

Main Methods:

• Review of existing literature on B cell biology and targeted therapies.
• Analysis of clinical outcomes and mechanisms of B cell depleting therapies.
• Discussion of novel therapeutic strategies including B cell receptor signaling inhibition.

Main Results:

• B cell depleting therapies, while effective, can sometimes exacerbate autoimmune conditions.
• The existence of regulatory B cell populations complicates B cell targeted treatment strategies.
• Various therapeutic approaches are being explored, including anti-CD20, anti-CD19, anti-CD22 antibodies, CAR T cells, and BTK inhibitors.

Conclusions:

• B cell modulating therapies offer promising avenues for treating autoimmune diseases.
• Understanding the balance between effector and regulatory B cells is crucial for optimizing treatment.
• Further research is needed to refine these therapies, particularly for conditions like pemphigus.